Subject: A survey to assess the usage pattern of fluvoxamine in the management of Obsessive-Compulsive Disorder in India.
OCD is characterized by the presence of obsessions and/or compulsions. Obsessions are repetitive and persistent thoughts, images, impulses or urges that are intrusive and unwanted, and are commonly associated with anxiety. Compulsions are repetitive behaviours or mental acts that the individual feels driven to perform in response to an obsession according to rigid rules, or to achieve a sense of ‘completeness’
More recent nationally representative surveys have confirmed that OCD has a lifetime prevalence of 2–3%, although figures vary across regions, and that it is associated with substantial comorbidity and morbidity . Few sociodemographic correlates of OCD or its symptomatology have been demonstrated in epidemiological studies . OCD is more common in females than in males in the community, whereas the ratio of females to males is often fairly even in clinical samples.
SSRIs are the first-line pharmacological treatment for OCD based on their evidence of efficacy, tolerability, safety and absence of abuse potential .
Fluvoxamine maleate is a selective serotonin reuptake inhibitor (SSRI) that belongs to a distinct chemical series: the 2-aminoethyl oxime ethers of aralkylketones.
Fluvoxamine IR started to be systematically tested in the treatment of obsessive-compulsive disorder (OCD) in the US in the late 1980s and gained US Food and Drug Administration (FDA) approval by the end of 1994.
Fluvoxamine is the only selective SRI that has been tested so far against a noradrenaline reuptake inhibitor, desipramine, in the acute treatment of OCD. Both the rate of response and the change from baseline to endpoint in YBOCS scores were significantly greater with fluvoxamine than with desipramine. Long-term maintenance treatment with fluvoxamine seems to reduce the risk of relapse, and there is some indication that lower dosages may also be effective
This survey is conducted to assess the usage pattern of fluvoxamine in the management of obsessive- compulsive disorder in India.
As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})